FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134854889> ?p ?o ?g. }

• W3134854889 endingPage "475" @default.
• W3134854889 startingPage "475" @default.
• W3134854889 abstract "Gallbladder (GBC) is an aggressive form of cancer and most patients present with advanced unresectable disease due to lack of early signs and symptoms. This retrospective study was conducted to present the treatment outcomes with three lines of chemotherapies in a subset of patients with advanced, unresectable GBC with the primary objective to determine the response rates with nab-paclitaxel as the third-line chemotherapy after failure of the first-line gemcitabine and platinum and the second-line FOLFOX-4 (oxaliplatin, leucovorin and 5-FU) therapy. Another objective was to evaluate the toxicity, progression-free survival (PFS) and overall survival (OS).Treatment-naive patients with histologically proven inoperable GBC treated with gemcitabine/platinum, FOLFOX-4 and nab-paclitaxel as the first-, second- and third-line chemotherapy were included in this study. The dose of gemcitabine and cisplatin or carboplatin was 1 g/m[2] on days 1 and 8 and 75 mg/m[2] (or target AUC of 5) on day 1, in a 21-day cycle. FOLFOX-4 was administered every two weeks and nab-paclitaxel was administered as 125 mg/m[2] on days 1, 8 and 15 in a 28-day cycle.There were eight men and 13 women with a median age of 57 yr who received nab-paclitaxel therapy. The overall response rate of the first-, second- and third-line chemotherapy was 61.9, 57.1 and 52.4 per cent, respectively. The median PFS for the gemcitabine/platinum, FOLFOX-4 and nab-paclitaxel therapy was 5.5, 5.4 and 2.9 months, respectively. The median OS with three lines of therapies was 14.0 months. Common Terminology Criteria (CTC) grade 3 or 4 haematological toxicities were observed in 28.6, 38.1 and 23.8 per cent of patients on gemcitabine/platinum, FOLFOX-4 and nab-paclitaxel therapy, respectively.Our study suggests the clinical benefit of nab-paclitaxel chemotherapy in prolonging OS in a selected subgroup of advanced, unresectable GBC patients after failure of the first-line gemcitabine and platinum and the second-line FOLFOX-4 therapy." @default.
• W3134854889 created "2021-03-15" @default.
• W3134854889 creator A5051311967 @default.
• W3134854889 creator A5071654349 @default.
• W3134854889 creator A5082257836 @default.
• W3134854889 creator A5083744967 @default.
• W3134854889 creator A5085996586 @default.
• W3134854889 date "2020-01-01" @default.
• W3134854889 modified "2023-10-16" @default.
• W3134854889 title "Nab-paclitaxel: An effective third-line chemotherapy in patients with advanced, unresectable gallbladder cancer" @default.
• W3134854889 cites W2019607817 @default.
• W3134854889 cites W2025769688 @default.
• W3134854889 cites W2052257197 @default.
• W3134854889 cites W2073810888 @default.
• W3134854889 cites W2087336559 @default.
• W3134854889 cites W2106550415 @default.
• W3134854889 cites W2113152482 @default.
• W3134854889 cites W2115261608 @default.
• W3134854889 cites W2129001123 @default.
• W3134854889 cites W2176027801 @default.
• W3134854889 cites W2196479442 @default.
• W3134854889 cites W2200769448 @default.
• W3134854889 cites W2401765700 @default.
• W3134854889 cites W2589804576 @default.
• W3134854889 cites W2593246153 @default.
• W3134854889 cites W2895926103 @default.
• W3134854889 doi "https://doi.org/10.4103/ijmr.ijmr_930_18" @default.
• W3134854889 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8157893" @default.
• W3134854889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33707389" @default.
• W3134854889 hasPublicationYear "2020" @default.
• W3134854889 type Work @default.
• W3134854889 sameAs 3134854889 @default.
• W3134854889 citedByCount "3" @default.
• W3134854889 countsByYear W31348548892020 @default.
• W3134854889 countsByYear W31348548892022 @default.
• W3134854889 countsByYear W31348548892023 @default.
• W3134854889 crossrefType "journal-article" @default.
• W3134854889 hasAuthorship W3134854889A5051311967 @default.
• W3134854889 hasAuthorship W3134854889A5071654349 @default.
• W3134854889 hasAuthorship W3134854889A5082257836 @default.
• W3134854889 hasAuthorship W3134854889A5083744967 @default.
• W3134854889 hasAuthorship W3134854889A5085996586 @default.
• W3134854889 hasBestOaLocation W31348548891 @default.
• W3134854889 hasConcept C121608353 @default.
• W3134854889 hasConcept C126322002 @default.
• W3134854889 hasConcept C143998085 @default.
• W3134854889 hasConcept C2776534502 @default.
• W3134854889 hasConcept C2776694085 @default.
• W3134854889 hasConcept C2777292972 @default.
• W3134854889 hasConcept C2778239845 @default.
• W3134854889 hasConcept C2778260052 @default.
• W3134854889 hasConcept C2780258809 @default.
• W3134854889 hasConcept C2780962732 @default.
• W3134854889 hasConcept C2781451048 @default.
• W3134854889 hasConcept C526805850 @default.
• W3134854889 hasConcept C71924100 @default.
• W3134854889 hasConcept C90924648 @default.
• W3134854889 hasConceptScore W3134854889C121608353 @default.
• W3134854889 hasConceptScore W3134854889C126322002 @default.
• W3134854889 hasConceptScore W3134854889C143998085 @default.
• W3134854889 hasConceptScore W3134854889C2776534502 @default.
• W3134854889 hasConceptScore W3134854889C2776694085 @default.
• W3134854889 hasConceptScore W3134854889C2777292972 @default.
• W3134854889 hasConceptScore W3134854889C2778239845 @default.
• W3134854889 hasConceptScore W3134854889C2778260052 @default.
• W3134854889 hasConceptScore W3134854889C2780258809 @default.
• W3134854889 hasConceptScore W3134854889C2780962732 @default.
• W3134854889 hasConceptScore W3134854889C2781451048 @default.
• W3134854889 hasConceptScore W3134854889C526805850 @default.
• W3134854889 hasConceptScore W3134854889C71924100 @default.
• W3134854889 hasConceptScore W3134854889C90924648 @default.
• W3134854889 hasIssue "5" @default.
• W3134854889 hasLocation W31348548891 @default.
• W3134854889 hasLocation W31348548892 @default.
• W3134854889 hasLocation W31348548893 @default.
• W3134854889 hasLocation W31348548894 @default.
• W3134854889 hasOpenAccess W3134854889 @default.
• W3134854889 hasPrimaryLocation W31348548891 @default.
• W3134854889 hasRelatedWork W1507774806 @default.
• W3134854889 hasRelatedWork W1970921743 @default.
• W3134854889 hasRelatedWork W2069788606 @default.
• W3134854889 hasRelatedWork W2100029565 @default.
• W3134854889 hasRelatedWork W2162526231 @default.
• W3134854889 hasRelatedWork W2419621113 @default.
• W3134854889 hasRelatedWork W2443311901 @default.
• W3134854889 hasRelatedWork W248568554 @default.
• W3134854889 hasRelatedWork W2748211320 @default.
• W3134854889 hasRelatedWork W4250038123 @default.
• W3134854889 hasVolume "152" @default.
• W3134854889 isParatext "false" @default.
• W3134854889 isRetracted "false" @default.
• W3134854889 magId "3134854889" @default.
• W3134854889 workType "article" @default.